Genetically engineered T cells with reduced TGF-beta receptor signaling

Genetically modified T cells with disrupted TGFBR2 signaling overcome the immunosuppressive effects of TGF-β in the tumor microenvironment, ensuring sustained cytotoxicity and proliferation, thus improving the efficacy of CAR-T and TCR-T therapies against solid tumors.

JP2024541081AInactive Publication Date: 2024-11-06NEOGENE THERAPEUTICS BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529251
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-04-30
Filing Date
2022-11-14
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

CAR-T and TCR-T cell approaches have shown poorer efficacy against solid tumors due to the immunosuppressive tumor microenvironment, particularly influenced by the immunosuppressive cytokine TGF-β, which limits anti-tumor immune responses by suppressing T cell functions.

Method used

Genetically engineered T cells with targeted disruption of the TGFBR2 gene to reduce receptor surface expression and TGF-β-induced signaling, allowing T cells to maintain proliferation and cytotoxicity in the presence of TGF-β, achieved through genomic modifications using RNA-guided nucleases like CRISPR-Cas9.

Benefits of technology

The engineered T cells demonstrate resistance to TGF-β-mediated suppression, maintaining cytotoxic function and proliferation capabilities, even in the presence of physiologically relevant levels of TGF-β, thereby enhancing their effectiveness against solid tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541081000004
    Figure 2024541081000004
  • Figure 2024541081000005
    Figure 2024541081000005
  • Figure 2024541081000006
    Figure 2024541081000006
Patent Text Reader

Abstract

Provided are T cells comprising engineered genomic modifications of the TGFBR2 gene. The genomic modifications can reduce receptor surface expression and / or reduce TGF-β-induced signaling, and allow T cells with such TGFBR2 disruption to continue to proliferate and kill target tumor cells even in the presence of physiologically relevant levels of TGF-β. In a preferred embodiment, the T cells are further engineered to express a CAR or an exogenous TCR. Also provided are methods of producing engineered T cells, pharmaceutical compositions comprising populations of such T cells, and methods of treatment.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Human T cells redirected to recognize antigens expressed on tumor cells, either through expression of a chimeric antigen receptor ("CAR") or expression of a foreign T cell receptor (TCR), have proven effective in treating certain hematological cancers. However, to date, CAR-T and TCR-T approaches have shown poorer efficacy against solid tumors, in part due to the presence of an immunosuppressive tumor microenvironment. There is a need for improved CAR-T and TCR-T cell approaches that can overcome the suppressive tumor microenvironment of solid tumors.

[0002] Transforming growth factor beta ("TGF-β") is an immunosuppressive cytokine found in the tumor microenvironment of some solid cancers, including advanced metastatic solid cancers. In some circumstances, TGF-β can limit antitumor immune responses. One possible mechanism for the effects of TGF-β is the suppression of T cell functions, including T cell cytotoxicity, proliferation, and cytokine production. Without limiting the present invention, it is currently believed that TGF-β binds to the extracellular domain of transforming growth factor beta receptor 2 ("TGFBR2") and promotes dimerization of TGFBR1 and TGFBR2. After receptor dimerization, the TGFBR2 kinase domain transphosphorylates TGFBR1, leading to downstream phosphorylation of SMAD2 and SMAD3 and subsequent expression of TGF-β responsive genes. Summary of the Invention [Means for solving the problem]

[0003] The inventors have now discovered that targeted disruption of the TGFBR2 gene can reduce receptor surface expression and / or reduce TGF-β-induced signaling, and enable TCR-T cells with such a TGFBR2 disruption to continue to proliferate and kill target tumor cells in the presence of physiologically relevant levels of TGF-β.

[0004] Thus, in a first aspect, the disclosure provides a T cell comprising an engineered genomic modification of a TGFBR2 gene, wherein the engineered genomic modification results in a level of surface-expressed TGFBR2 or a detectable portion thereof that is about 20% to about 60% of the level of surface-expressed TGFBR2 on a corresponding control cell. In some embodiments, the genomic modification is in exon 4 of the TGFBR2 gene. In some embodiments, the T cell expresses an exogenous TCR or CAR, preferably an exogenous TCR.

[0005] In another aspect, a T cell is provided that comprises an engineered genomic modification of the TGFBR2 gene, the modification resulting in a truncated surface expressed TGFBR2. In some embodiments, the genomic modification is in exon 4 of the TGFBR2 gene. In some embodiments, the T cell expresses an exogenous TCR or CAR, preferably an exogenous TCR. In some embodiments, the TCR or CAR is integrated into the genome of the T cell at a defined location. In certain embodiments, the integration is performed using CRISPR, optionally CRISPR-Cas9.

[0006] In another aspect, a method of making such engineered T cells is provided. In another aspect, a pharmaceutical composition comprising such engineered T cells is provided. In a further aspect, a method of treating a patient is provided comprising administering to the patient a therapeutically effective amount of the engineered T cells or a pharmaceutical composition comprising such engineered T cells.

[0007] These and other features, aspects and advantages of the present invention will become better understood with consideration of the following description and accompanying drawings. [Brief description of the drawings]

[0008] [Figure 1]A schematic diagram is provided depicting the exon structure of the human TGF-β receptor 2 gene ("TGFBR2"). The human TGFBR2 gene contains seven exons that encode, from N-terminus to C-terminus, the extracellular domain, the transmembrane domain, and the kinase domain. Binding sites for the guide RNAs ("gRNAs") used to direct RNA-guided nucleases to exon 1 (TGFBR2 gRNA1-gRNA7) and exon 4 (TGFBR2 gRNA15-gRNA22), respectively, are shown. The gRNA target sequences are presented in Table 2. [Figure 2A] Data are presented showing that RNA-guided nuclease editing to disrupt the TGFBR2 gene renders T cells resistant to TGF-β-induced phospho-Smad2 / 3 upregulation. Healthy donor human T cells were engineered to express 1G4 TCR and then electroporated with various TGFBR2 gRNA RNP complexes. 1G4 TCR-expressing TGFBR2-edited T cells were then cultured in duplicate for 30 min in the presence or absence of TGF-β (20 ng / mL) and then stained intracellularly with an antibody that detects phosphorylated Smad2 / 3 protein. Figure 2A presents flow cytometry histograms depicting phospho-Smad2 / 3 expression after treatment with (gray) or without (black) TGF-β. Peak sizes were normalized to the mode for each curve. [Figure 2B]Data are presented showing that RNA-guided nuclease editing to disrupt the TGFBR2 gene renders T cells resistant to TGF-β-induced phospho-Smad2 / 3 upregulation. Healthy donor human T cells were engineered to express 1G4 TCR and then electroporated with various TGFBR2 gRNA RNP complexes. 1G4 TCR-expressing TGFBR2-edited T cells were then cultured in duplicate for 30 minutes in the presence or absence of TGF-β (20 ng / mL) and then stained intracellularly with an antibody that detects phosphorylated Smad2 / 3 protein. Figure 2B summarizes the fold change in phospho-Smad2 / 3 median fluorescence intensity ("MFI") in response to TGF-β treatment. Error bars indicate standard deviation of duplicates. [Diagram 3] We present data showing that disrupting the TGFBR2 gene in T cells by RNA-guided nuclease editing results in reduced TGFBR2 surface expression. Healthy donor human T cells were engineered to express 1G4 TCR and then electroporated with various clinical-grade TGFBR2 gRNA RNP complexes targeting the extracellular domain ("ECD") (gRNAs 1 and 4-7) or the intracellular kinase domain ("ICD") (gRNAs 15-17, 20 and 22) of TGFBR2. Four days after editing, TGFBR2 surface expression was analyzed by surface staining with an anti-TGFBR2 antibody. TGFBR2 expression is normalized to the median TGFBR2 fluorescence intensity in T cells engineered to express 1G4 TCR without TGFBR2 gene editing. Error bars indicate standard deviation of duplicates. [Figure 4A]Data are presented showing that T cells with nuclease-mediated disruptions in the TGFBR2 gene have superior cytotoxic function after repeated tumor cell challenge in the presence of TGF-β. 1G4 TCR-expressing T cells (control) and 1G4 TCR-expressing T cells with various edited disruptions to the TGFBR2 gene were subjected to repeated cytotoxicity assays using the IncuCyte platform. T cells were cultured with A375-GFP+ target cells at a 5:1 effector-to-target ratio in the presence or absence of exogenous TGF-β (20 ng / mL) for approximately 72 hours before being harvested and recultured with fresh A375-GFP+ cells for a total of four times. A375-GFP+ cell death was quantified by imaging every 2 hours using a 10× objective and counting the GFP+ cells remaining in the culture. FIG. 4A shows the number of A375-GFP+ cells when A375-GFP+ target cells were cultured with or without TGF-β in the presence of T cells lacking exogenous 1G4 TCR and without any edits to the TGFBR2 gene ("non-edited"), 1G4-expressing T cells lacking edits to the TGFBR2 gene ("1G4 TCR only"), and no T cells ("no T cells"). [Figure 4B]Data are presented showing that T cells with nuclease-mediated disruptions in the TGFBR2 gene have superior cytotoxic function after repeated tumor cell challenge in the presence of TGF-β. 1G4 TCR-expressing T cells (control) and 1G4 TCR-expressing T cells with various edited disruptions to the TGFBR2 gene were subjected to repeated cytotoxicity assays using the IncuCyte platform. T cells were cultured with A375-GFP+ target cells at a 5:1 effector-to-target ratio in the presence or absence of exogenous TGF-β (20 ng / mL) for approximately 72 hours before being harvested and recultured with fresh A375-GFP+ cells for a total of four times. A375-GFP+ cell death was quantified by imaging every 2 hours using a 10× objective and counting the GFP+ cells remaining in the culture. FIG. 4B shows the number of A375-GFP+ cells when A375-GFP+ target cells were cultured with or without TGF-β in the presence of T cells expressing an exogenous 1G4 TCR and in which the TGFBR2 gene was disrupted using exon 1 targeting gRNAs (TGFBR2-1 to TGFBR2-7). [Figure 4C]Data are presented showing that T cells with nuclease-mediated disruptions in the TGFBR2 gene have superior cytotoxic function after repeated tumor cell challenge in the presence of TGF-β. 1G4 TCR-expressing T cells (control) and 1G4 TCR-expressing T cells with various edited disruptions to the TGFBR2 gene were subjected to repeated cytotoxicity assays using the IncuCyte platform. T cells were cultured with A375-GFP+ target cells at a 5:1 effector-to-target ratio in the presence or absence of exogenous TGF-β (20 ng / mL) for approximately 72 hours before being harvested and recultured with fresh A375-GFP+ cells for a total of four times. A375-GFP+ cell death was quantified by imaging every 2 hours using a 10× objective and counting the GFP+ cells remaining in the culture. Figure 4C shows the number of A375-GFP+ cells when A375-GFP+ target cells were cultured with or without TGF-β in the presence of T cells expressing exogenous 1G4 TCR and in which the TGFBR2 gene was disrupted using exon 4 targeting gRNA (TGFBR2-15, TGFBR2-16, TGFBR2-17, TGFBR2-20, TGFBR2-22). Error bars indicate standard deviation of triplicates. [Figure 4D]Data are presented showing that T cells with nuclease-mediated disruptions in the TGFBR2 gene have superior cytotoxic function after repeated tumor cell challenge in the presence of TGF-β. 1G4 TCR-expressing T cells (control) and 1G4 TCR-expressing T cells with various edited disruptions to the TGFBR2 gene were subjected to repeated cytotoxicity assays using the IncuCyte platform. T cells were cultured with A375-GFP+ target cells at a 5:1 effector-to-target ratio in the presence or absence of exogenous TGF-β (20 ng / mL) for approximately 72 hours before being harvested and recultured with fresh A375-GFP+ cells for a total of four times. A375-GFP+ cell death was quantified by imaging every 2 hours using a 10× objective and counting the GFP+ cells remaining in the culture. Figure 4D is a histogram summarizing the number of A375-GFP+ cells after four challenges. Error bars indicate standard deviation of triplicates. [Diagram 5] Data are presented demonstrating that T cells with a nuclease-mediated disruption in the TGFBR2 gene maintain their proliferative potential in the presence of TGF-β. TGFBR2-disrupted 1G4 TCR-expressing T cells were subjected to repeated restimulation with ImmunoCult (10 μL / mL) in the presence or absence of exogenous TGF-β (20 ng / mL). T cell proliferation was quantified by counting T cells every week. Error bars indicate standard deviation of duplicates. [Figure 6] Data are presented demonstrating that nuclease-mediated disruption of the TGFBR2 gene does not alter the expression of exogenous TCR. Cells were stained with antibodies detecting endogenous TCR ("huTCR") or exogenous TCR marked with the mur6 epitope ("mur6"). FACS plots of knock-in TCR were similar between the three different disruption sites 7 days after electroporation and 14 days after electroporation and selection of cells containing the TCR repair template. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] 4.1.Definition A "corresponding control cell" is a cell that is as closely identical to the modified cell as scientifically acceptable and practical to make a scientifically valid comparison. Other than the genomic modification to be compared, a suitable control cell must have the same cell type, the same growth conditions, and / or the same other modifications. Those skilled in the art will understand what variables, parameters, and conditions are relevant in any given situation to determine any differences (e.g., changes in the level of surface expression) due to the genomic modification. The contents of this application provide examples of suitable control cells in specific situations.

[0010] 4.2. T Cells Containing an Engineered Genomic Modification of the TGFBR2 Gene In a first aspect, a T cell is provided that comprises an engineered genomic modification of the TGFBR2 gene, the engineered genomic modification resulting in a level of surface-expressed TGFBR2, or a detectable portion thereof, that is about 20% to about 60% of the level of surface-expressed TGFBR2 on a corresponding control cell.

[0011] In some embodiments, the engineered genomic modifications result in a level of surface-expressed TGFBR2 or a detectable portion thereof that is about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60% of the level of surface-expressed TGFBR2 on a corresponding control cell. In some embodiments, the engineered genomic modifications result in a level of surface-expressed TGFBR2 or a detectable portion thereof that is no more than about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60% of the level of surface-expressed TGFBR2 on a corresponding control cell.

[0012] In some embodiments, the T cell is a CD8+ αβ T cell, a CD4+ αβ T cell, or a γδ T cell. In some embodiments, the T cell is a human T cell. In some human T cell embodiments, the T cell is obtained from a cancer patient. In some human T cell embodiments, the T cell is obtained from a healthy subject. In some human T cell embodiments, the T cell is the progeny of a T cell obtained from a cancer patient or obtained from a healthy subject.

[0013] In some embodiments, surface-expressed TGFBR2 or a detectable portion thereof is capable of binding TGF-β but is unable to phosphorylate TGFBR1, hi some embodiments, T cells are unable to effectively signal through Smad2 / 3 in response to contact of the T cells with physiologically relevant levels of TGF-β.

[0014] In various embodiments, the engineered genomic modifications include one or more of: (i) insertions and / or deletions in the TGFBR2 gene promoter; (ii) frameshift insertions and / or deletions in exons of the TGFBR2 gene; (iii) deletions of part, but not all, of the coding region of the TGFBR2 gene; (iv) substitutions, insertions and / or deletions that create a stop codon in an exon upstream of the native stop codon; and (v) substitutions, insertions and / or deletions that modify one or more donor and / or acceptor RNA splice sites within the TGFBR2 gene.

[0015] In certain embodiments, the genomic modification is in exon 1 of the TGFBR2 gene, exon 2 of the TGFBR2 gene, exon 3 of the TGFBR2 gene, exon 4 of the TGFBR2 gene, exon 5 of the TGFBR2 gene, exon 6 of the TGFBR2 gene, or exon 7 of the TGFBR2 gene. In certain embodiments, the genomic modification is in exon 4 of the TGFBR2 gene.

[0016] In various embodiments, genome modification is accomplished by RNA-guided nuclease. In some embodiments, the RNA-guided nuclease is a double-stranded break-inducing nuclease. In some embodiments, the RNA-guided nuclease is a single-stranded break-inducing nuclease (nickase). In some embodiments, the RNA-guided nuclease is fused to a second enzyme. In certain embodiments, the second enzyme is a reverse transcriptase.

[0017] In certain embodiments, the genomic modification is a frameshift caused by cleavage by an RNA-guided nuclease between bases 294 and 295, 389 and 390, 543 and 544, 547 and 548, or 674 and 675 of exon 4 (SEQ ID NO: 2) of the TGFBR2 gene.

[0018] In some embodiments, the T cells express an exogenous TCR or CAR. In certain embodiments, the TCR is introduced into the T cells using a viral method. In certain embodiments, the TCR is introduced into the T cells using a method (e.g., CRISPR-Cas9 or other CRISPR enzymes) that integrates a gene for expressing the exogenous TCR into a specific site in the genome of the T cells.

[0019] In certain preferred embodiments, the T cell expresses an exogenous TCR. In certain embodiments, the T cell continues to express its endogenous TCR. In certain embodiments, the T cell does not express its endogenous TCR.

[0020] In certain embodiments, the T cells express a CAR. In certain embodiments, the CAR is a first generation CAR. In some embodiments, the CAR is a second generation CAR. In some embodiments, the CAR is a CAR similar to that described in U.S. Pat. No. 10,703,794, the disclosure of which is incorporated herein by reference in its entirety. In some embodiments, the CAR is an NKG2D-based CAR described in WO2021 / 058563, the disclosure of which is incorporated herein by reference in its entirety.

[0021] In some embodiments, the foreign TCR or CAR recognizes a tumor antigen. As will be understood by one of skill in the art, the "antigen" recognized by the TCR is a peptide-HLA complex (pHLA). In some embodiments, the tumor antigen is a tumor-associated antigen that is also expressed by non-tumor cells. In some embodiments, the tumor antigen is a cancer / testis antigen. In some embodiments, the tumor antigen is a neo-antigen. In certain embodiments, the neo-antigen is a common, i.e., widely known, tumor neo-antigen. In certain embodiments, the neo-antigen is a non-common, i.e., individual, neo-antigen.

[0022] In some embodiments, the T cells maintain the ability to kill a population of target cells expressing an antigen recognized by an exogenous TCR or CAR in vitro in the presence of physiologically relevant levels of TGF-β after at least two exposure events to the target cells. In some embodiments, the T cells maintain the ability to kill a population of target cells expressing an antigen recognized by an exogenous TCR or CAR in vitro in the presence of physiologically relevant levels of TGF-β for at least about 72, 80, 90, 100, 110, 120, 130, 140, 144, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 288 hours.

[0023] In another embodiment, a T cell is provided that comprises an engineered genomic modification of the TGFBR2 gene, the modification resulting in a surface-expressed TGFBR2 that is a truncated form.

[0024] In some embodiments, the T cell is a CD8+ αβ T cell, a CD4+ αβ T cell, or a γδ T cell. In some embodiments, the T cell is a human T cell. In some human T cell embodiments, the T cell is obtained from a cancer patient. In some human T cell embodiments, the T cell is obtained from a healthy subject. In some human T cell embodiments, the T cell is the progeny of a T cell obtained from a cancer patient or obtained from a healthy subject.

[0025] In some embodiments, surface-expressed truncated TGFBR2 is capable of binding TGF-β but is unable to phosphorylate TGFBR1. In some embodiments, T cells are unable to effectively signal through Smad2 / 3 in response to contact of the T cells with physiologically relevant levels of TGF-β.

[0026] In some embodiments, the engineered genomic modification comprises one or more of: (i) a frameshift insertion and / or deletion in exon 4 of the TGFBR2 gene; (ii) a deletion of exons 5-7 of the TGFBR2 gene, optionally combined with a total or partial deletion of exon 4; and (iii) a substitution, insertion and / or deletion in exon 4 creating a premature stop codon.

[0027] In certain embodiments, the genomic modification is in exon 1 of the TGFBR2 gene, exon 2 of the TGFBR2 gene, exon 3 of the TGFBR2 gene, exon 4 of the TGFBR2 gene, exon 5 of the TGFBR2 gene, exon 6 of the TGFBR2 gene, or exon 7 of the TGFBR2 gene. In certain embodiments, the genomic modification is in exon 4 of the TGFBR2 gene.

[0028] In various embodiments, genome modification is accomplished by RNA-guided nuclease. In some embodiments, the RNA-guided nuclease is a double-stranded break-inducing nuclease. In some embodiments, the RNA-guided nuclease is a single-stranded break-inducing nuclease (nickase). In some embodiments, the RNA-guided nuclease is fused to a second enzyme. In certain embodiments, the second enzyme is a reverse transcriptase.

[0029] In certain embodiments, the genomic modification is a frameshift caused by cleavage by an RNA-guided nuclease between bases 294 and 295, 389 and 390, 543 and 544, 547 and 548, or 674 and 675 of exon 4 (SEQ ID NO: 2) of the TGFBR2 gene.

[0030] In some embodiments, the T cells express an exogenous TCR or CAR. In certain embodiments, the TCR is introduced into the T cells using a viral method. In certain embodiments, the TCR is introduced into the T cells using a method (e.g., CRISPR-Cas9 or other CRISPR enzymes) that integrates a gene for expressing the exogenous TCR into a specific site in the genome of the T cells.

[0031] In certain preferred embodiments, the T cell expresses an exogenous TCR. In certain embodiments, the T cell continues to express its endogenous TCR. In certain embodiments, the T cell does not express its endogenous TCR.

[0032] In certain embodiments, the T cells express a CAR. In certain embodiments, the CAR is a first generation CAR. In some embodiments, the CAR is a second generation CAR. In some embodiments, the CAR is a CAR similar to that described in U.S. Pat. No. 10,703,794, the disclosure of which is incorporated herein by reference in its entirety. In some embodiments, the CAR is an NKG2D-based CAR described in WO2021 / 058563, the disclosure of which is incorporated herein by reference in its entirety.

[0033] In some embodiments, the T cells express an exogenous TCR or CAR that recognizes a tumor antigen. As will be understood by one of skill in the art, the "antigen" recognized by the TCR is a peptide-HLA complex (pHLA). In some embodiments, the tumor antigen is a tumor-associated antigen that is also expressed by non-tumor cells. In some embodiments, the tumor antigen is a cancer / testis antigen. In some embodiments, the tumor antigen is a neo-antigen. In certain embodiments, the neo-antigen is a common, i.e., widely known, tumor neo-antigen. In certain embodiments, the neo-antigen is a non-common, i.e., individual, neo-antigen.

[0034] In some embodiments, the T cells maintain the ability to kill a population of target cells expressing an antigen recognized by an exogenous TCR or CAR in vitro in the presence of physiologically relevant levels of TGF-β after at least two exposure events to the target cells. In some embodiments, the T cells maintain the ability to kill a population of target cells expressing an antigen recognized by an exogenous TCR or CAR in vitro in the presence of physiologically relevant levels of TGF-β for at least about 72, 80, 90, 100, 110, 120, 130, 140, 144, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 288 hours.

[0035] In some embodiments, the T cells have an enhanced cytokine response after contact or exposure to a tumor or other cell line that presents an antigen recognized by the TCR expressed by the T cell, in certain embodiments, the cytokine is interferon-gamma, interleukin-2, or tumor necrosis factor-alpha.

[0036] Pharmaceutical Compositions In another aspect, there is provided a pharmaceutical composition comprising a T cell as described herein and a pharma- ceutical acceptable carrier. In a preferred embodiment, the T cell expresses an exogenous TCR or CAR.

[0037] In various embodiments, the pharmaceutical composition comprises a population of T cells as described herein. In certain embodiments, the T cells express an exogenous TCR or CAR. In certain embodiments, all of the T cells in the population express the same exogenous TCR. In certain embodiments, all of the T cells in the population express the same CAR. In certain embodiments, the pharmaceutical composition comprises a T cell as described herein, and the T cells in the population collectively express multiple CARs.

[0038] In some embodiments, the pharmaceutical composition is adapted for administration by intravenous infusion, hi some embodiments, the composition is adapted for intratumoral administration.

[0039] 4.4. Methods for genetically engineering T cells In another aspect, a method of making a TGFBR2-modified T cell as described herein is provided. In some embodiments, the method comprises modifying a TGFBR2 gene in a T cell genome, wherein after gene modification, the level of surface-expressed TGFBR2 or a detectable portion thereof is about 20% to about 60% of the level of surface-expressed TGFBR2 on a corresponding control cell.

[0040] In some embodiments, the engineered genomic modifications result in a level of surface-expressed TGFBR2 or a detectable portion thereof that is about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60% of the level of surface-expressed TGFBR2 on a corresponding control cell. In some embodiments, the engineered genomic modifications result in a level of surface-expressed TGFBR2 or a detectable portion thereof that is no more than about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60% of the level of surface-expressed TGFBR2 on a corresponding control cell.

[0041] In some embodiments, the T cell is a CD8+ αβ T cell, a CD4+ αβ T cell, or a γδ T cell. In some embodiments, the T cell is a human T cell. In some human T cell embodiments, the T cell is obtained from a cancer patient. In some human T cell embodiments, the T cell is obtained from a healthy subject. In some human T cell embodiments, the T cell is the progeny of a T cell obtained from a cancer patient or obtained from a healthy subject.

[0042] In some embodiments, surface-expressed TGFBR2 or a detectable portion thereof is capable of binding TGF-β but is unable to phosphorylate TGFBR1, hi some embodiments, T cells are unable to effectively signal through Smad2 / 3 in response to contact of the T cells with physiologically relevant levels of TGF-β.

[0043] In some embodiments, the modification is one or more of: (i) an insertion and / or deletion in the TGFBR2 gene promoter, (ii) a frameshift insertion and / or deletion in an exon of the TGF-βIIR gene, (iii) a deletion of part, but not all, of the coding region of the TGFBR2 gene, (iv) a substitution, insertion and / or deletion that creates a stop codon in an exon upstream of the native stop codon, and (v) a substitution, insertion and / or deletion that modifies one or more donor and / or acceptor RNA splice sites within the TGFBR2 gene. In a particular embodiment, the modification is in exon 4 of the TGFBR2 gene.

[0044] In some embodiments, modifying comprises introducing an RNA-guided nuclease and at least one RNA guide into the T cell. In some embodiments, the RNA-guided nuclease is a double-strand break-inducing nuclease. In some embodiments, the RNA-guided nuclease is a single-strand break-inducing nuclease (nickase). In some embodiments, the RNA-guided nuclease is fused to a second enzyme. In certain embodiments, the second enzyme is a reverse transcriptase.

[0045] In some embodiments, the RNA-guided nuclease cleaves exon 4 (SEQ ID NO: 2) of the TGFBR2 gene between bases 294 and 295, 389 and 390, 543 and 544, 547 and 548, or 674 and 675. In certain embodiments, at least one guide RNA has the sequence of SEQ ID NO: 8-12.

[0046] In some embodiments, the method further comprises a subsequent step of selecting T cells that have the desired genomic modification.

[0047] In some embodiments, the method further comprises a step of genetically engineering the T cells to express a CAR or an exogenous TCR before or after modifying the TGFBR2 gene. In certain embodiments, the T cells are genetically engineered to express an exogenous TCR. In certain embodiments, the TCR is introduced into the T cells using a viral method. In certain embodiments, the TCR is introduced into the T cells using a method (e.g., CRISPR-Cas9 or other CRISPR enzymes) that integrates a gene for expressing the exogenous TCR at a specific site in the genome of the T cells. In some embodiments, the T cells express their endogenous TCR in parallel. In some embodiments, the T cells are further genetically engineered not to express their endogenous TCR.

[0048] In some embodiments, the foreign TCR or CAR recognizes a tumor antigen. In some embodiments, the tumor antigen is a tumor-associated antigen that is also expressed by non-tumor cells. In some embodiments, the tumor antigen is a cancer / testis antigen. In some embodiments, the tumor antigen is a neo-antigen. In certain embodiments, the neo-antigen is a common, i.e., widely known, tumor neo-antigen. In certain embodiments, the neo-antigen is a non-common, i.e., individual, neo-antigen.

[0049] In various embodiments, after modification of the TGFBR2 gene and further engineering the T cells to express a CAR or exogenous TCR, the T cells maintain the ability to kill a population of target cells expressing an antigen recognized by the exogenous TCR or CAR in vitro in the presence of physiologically relevant levels of TGF-β after at least two exposure events to the target cells. In some embodiments, the T cells maintain the ability to kill a population of target cells expressing an antigen recognized by the exogenous TCR or CAR in vitro in the presence of physiologically relevant levels of TGF-β for at least about 72, 80, 90, 100, 110, 120, 130, 140, 144, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 288 hours.

[0050] In another aspect, a method is provided for making a TGFBR2 modified T cell as described herein, wherein the modification is within exon 4 and results in a surface expressed TGFBR2 that is truncated.

[0051] In some embodiments, the T cell is a CD8+ αβ T cell, a CD4+ αβ T cell, or a γδ T cell. In some embodiments, the T cell is a human T cell. In some human T cell embodiments, the T cell is obtained from a cancer patient. In some human T cell embodiments, the T cell is obtained from a healthy subject. In some human T cell embodiments, the T cell is the progeny of a T cell obtained from a cancer patient or obtained from a healthy subject.

[0052] In some embodiments, surface-expressed truncated TGFBR2 is capable of binding TGF-β but is unable to phosphorylate TGFBR1. In some embodiments, T cells are unable to effectively signal through Smad2 / 3 in response to contact of the T cells with physiologically relevant levels of TGF-β.

[0053] In some embodiments, cleaved surface-expressed TGFBR2 is present at a level equal to or greater than the amount of TGFBR2 present in unmodified T cells, in some embodiments, cleaved surface-expressed TGFBR2 is present at a level that is about 20%-60% of the level of TGFBR2 present in unmodified T cells.

[0054] In some embodiments, the engineered genomic modification comprises one or more of: (i) a frameshift insertion and / or deletion in exon 4 of the TGFBR2 gene; (ii) a deletion of exons 5-7 of the TGFBR2 gene, optionally combined with a total or partial deletion of exon 4; and (iii) a substitution, insertion and / or deletion in exon 4 creating a premature stop codon.

[0055] In some embodiments, modifying comprises introducing an RNA-guided nuclease and at least one RNA guide into the T cell. In some embodiments, the RNA-guided nuclease is a double-strand break-inducing nuclease. In some embodiments, the RNA-guided nuclease is a single-strand break-inducing nuclease (nickase). In some embodiments, the RNA-guided nuclease is fused to a second enzyme. In certain embodiments, the second enzyme is a reverse transcriptase.

[0056] In some embodiments, the RNA-guided nuclease cleaves exon 4 (SEQ ID NO: 2) of the TGFBR2 gene between bases 294 and 295, 389 and 390, 543 and 544, 547 and 548, or 674 and 675. In certain embodiments, at least one guide RNA has the sequence of SEQ ID NO: 8-12.

[0057] In some embodiments, the method further comprises a subsequent step of selecting T cells that have the desired genomic modification.

[0058] In some embodiments, the method further comprises a step of genetically engineering the T cells to express a CAR or an exogenous TCR before or after modifying the TGFBR2 gene. In certain embodiments, the T cells are genetically engineered to express an exogenous TCR. In certain embodiments, the TCR is introduced into the T cells using a viral method. In certain embodiments, the TCR is introduced into the T cells using a method (e.g., CRISPR-Cas9 or other CRISPR enzymes) that integrates a gene for expressing the exogenous TCR at a specific site in the genome of the T cells. In some embodiments, the T cells express their endogenous TCR in parallel. In some embodiments, the T cells are further genetically engineered not to express their endogenous TCR.

[0059] In some embodiments, the foreign TCR or CAR recognizes a tumor antigen. In some embodiments, the tumor antigen is a tumor-associated antigen that is also expressed by non-tumor cells. In some embodiments, the tumor antigen is a cancer / testis antigen. In some embodiments, the tumor antigen is a neo-antigen. In certain embodiments, the neo-antigen is a common, i.e., widely known, tumor neo-antigen. In certain embodiments, the neo-antigen is a non-common, i.e., individual, neo-antigen.

[0060] In various embodiments, after modification of the TGFBR2 gene and further engineering the T cells to express a CAR or exogenous TCR, the T cells maintain the ability to kill a population of target cells expressing an antigen recognized by the exogenous TCR or CAR in vitro in the presence of physiologically relevant levels of TGF-β after at least two exposure events to the target cells. In some embodiments, the T cells maintain the ability to kill a population of target cells expressing an antigen recognized by the exogenous TCR or CAR in vitro in the presence of physiologically relevant levels of TGF-β for at least about 72, 80, 90, 100, 110, 120, 130, 140, 144, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 288 hours.

[0061] In another aspect, there is provided a genetically engineered T cell produced by the methods described herein.

[0062] 4.5. Methods of Treating Disease In another aspect, a method is provided for treating a subject in need of treatment. In a typical embodiment, the subject is a human patient. The method comprises administering to the subject, typically a human patient, a therapeutically effective amount of a genetically engineered T cell as described herein or a pharmaceutical composition comprising such a genetically engineered T cell as described herein.

[0063] In some embodiments, the engineered T cells are engineered from T cells obtained from the patient to be treated or from the progeny of T cells obtained from the patient (autologous therapy). In some embodiments, the engineered T cells are engineered from T cells obtained from one or more individuals other than the patient to be treated or from the progeny of T cells obtained from that one or more individuals (allogeneic therapy).

[0064] In some embodiments, the engineered T cells are administered by intravenous infusion. In some embodiments, the engineered T cells are administered by intratumoral administration.

[0065] In some embodiments, the engineered T cells have an enhanced cytokine response after contact or exposure to a tumor or other cell line that presents an antigen recognized by the TCR expressed by the T cell. In certain embodiments, the cytokine is interferon-gamma or tumor necrosis factor-alpha. EXAMPLES

[0066] 4.6.1. Example 1: TGFBR2-disrupted TCR-expressing T cells are resistant to TGF-β signaling This example shows that disrupting the TGFBR2 gene in T cells that are further engineered to express an exogenous TCR reduces surface expression of TGFBR2 and renders the T cells resistant to TGF-β signaling.

[0067] gRNAs were synthesized that direct gene editing nucleases to various sites in human TGFBR2 exon 1 (extracellular domain of TGFBR2) or exon 4 (kinase domain of TGFBR2). Figure 1 is a schematic showing the location of the nuclease cleavage site induced by each gRNA. The sequences of exons 1 and 4 are provided in Table 1 below. Exon sequences are extracted from the Ensembl canonical transcript ENST00000295754.10. The target sequences of the gRNAs are provided in Table 2 below, where the TGFBR2 gRNA target sequence is indicated as (5'-3'), the predicted cleavage site is indicated as (|), and the PAM site is in bold. Table 2 further specifies whether the target is on the sense (+) or antisense (-) strand of the TGFBR2 gene.

[0068] [Table 1]

[0069] [Table 2]

[0070] Healthy donor human T cells were cultured at a 3:1 ratio (beads:CD3) for 48 h before electroporation with 1 µM TGFBR2-targeting RNP (CRISPR-Cas9 gRNA ribonucleoprotein) using a Lonza 4D nucleofector device, program EH-115. +The cells were activated with anti-CD3 / CD28 beads (Thermo Fisher, #40203D) and the endogenous TCR was knocked out and the expression of exogenous TCR (1G4) was induced. After expanding T cells for 7 days in AIM-V medium Thermo Fisher, #A3830801 containing 5% human serum Sigma-Aldrich, #H4522, 1% glutamax Thermo Fisher, #35050061, 5 μg / mL gentamicin Thermo Fisher, #15750037, IL-7 (5 ng / mL) Peprotech, #200-07 and IL-15 (5 ng / mL) Peprotech, #200-15, T cells were treated with or without TGF-β (20 ng / mL) R&D systems, #240-B-010 / CF for 30 minutes before staining intracellularly with an antibody detecting phosphorylated SMAD2 / 3 proteins BD Bioscience, #562696.

[0071] As shown in Figures 2A and 2B, T cells lacking both TGFBR2 editing and 1G4 TCR expression ("non-edited") and T cells lacking TGFBR2 editing but expressing exogenous 1G4 TCR ("1G4 only") showed an increase in phosphorylated SMAD2 / 3 after TGF-β treatment, whereas many of the TGFBR2-disrupted 1G4 TCR-expressing T cells did not demonstrate any increase. Some of the TGFBR2 exon 1-edited 1G4 TCR-expressing T cells and all of the TGFBR2 exon 4-edited 1G4 TCR-expressing T cells were completely resistant to TGF-β signaling.

[0072] As shown in Figure 3, gRNAs 4 and 7 directed edits to the TGFBR2 gene that were inefficient in reducing TGFBR2 surface expression on 1G4 TCR-expressing T cells. All other TGFBR2 gRNAs tested led to reduced TGFBR2 surface expression, including all gRNAs targeting exon 4 (Figure 3). TGFBR2 gRNAs targeting the intracellular kinase domain (exon 4) all reduced surface expression of TGFBR2 compared to control cells, however, exon 4 edited T cells showed a trend towards greater TGFBR2 surface expression compared to exon 1 (extracellular domain) edited cells (gRNAs TGFBR2-1, TGFBR2-5 and TGFBR2-6), which were successful in reducing surface expression. Surface expression data are presented in Table 3 below.

[0073] [Table 3]

[0074] 4.6.2. Example 2: TGFBR2-disrupted TCR-expressing T cells exhibit superior function in the presence of TGF-β This example demonstrates the ability of TGFBR2-disrupted T cells to maintain cytotoxic activity through multiple antigen exposures.

[0075] 1G4 TCR expressing TGFBR2 disrupted T cells were generated from healthy human donors as in Example 1. After expanding T cells for 14 days in AIM-V medium Thermo Fisher, #A3830801 containing 5% human serum Sigma-Aldrich, #H4522, 1% glutamax Thermo Fisher, #35050061, 5 μg / mL gentamicin Thermo Fisher, #15750037, IL-7 (5 ng / mL) Peprotech, #200-07 and IL-15 (5 ng / mL) Peprotech, #200-15, T cells were subjected to a repeat cytotoxicity assay using the IncuCyte platform.

[0076] T cells were incubated for approximately 72 hours with 1G4 TCR alloantigen, NY-ESO-1 and HLA-A in the presence or absence of exogenous TGF-β (20 ng / mL) R&D systems, #240-B-010 / CF. * T cells were then co-cultured with GFP-expressing A375 cells expressing a 02:01 peptide-HLA (pHLA) complex at an effector-to-target ratio of 5:1. T cells were then harvested and cultured with new A375-GFP T cells for a total of four tumor challenges. + Images were acquired every 2 hours using a 10× objective to assess T cell cytotoxicity by the GFP-positive cells remaining in the co-culture. + It was determined by counting the number of A375 cells.

[0077] During the first round, all 1G4 TCR-expressing T cells were transduced with A375-GFP in the presence or absence of TGF-β. + The cell proliferation was controlled (Figures 4A to 4D).

[0078] During the second round, non-TGFBR2-disrupted 1G4-expressing T cells ("1G4 TCR only") expressed A375-GFP in the presence of TGF-β. + TGFBR2-disrupted T cells, with reduced TGFBR2 expression and reduced TGF-β signaling capacity, were no longer able to control the proliferation of A375-GFP T cells during the second and subsequent rounds of tumor cell challenge, regardless of whether TGF-β was present or not. + TGFBR2 gRNA4-edited T cells and TGFBR2 gRNA7-edited T cells (Figure 2), which still retained some functional TGF-β signaling, were able to continue to kill cells in the presence of TGF-β at the beginning of the second round of killing. + and a reduced ability to control cell proliferation ( Fig. 4B ).

[0079] In the absence of exogenous TGF-β, 1G4 TCR-only T cells lost their cytotoxic function during the third and fourth rounds of tumor cell challenge, whereas TGFBR2-disrupted T cells maintained their cytotoxic function during the third and fourth rounds of tumor cell challenge in the absence of TGF-β. + The cell proliferation was controlled (Figures 4A, 4B and 4C). + The cell numbers are shown in FIG. 4D.

[0080] These data indicate that TGFBR2-disrupted T cells are resistant to TGF-β-mediated inhibition of cytotoxic function and are more potent at killing antigen-positive tumor cells in the presence or absence of exogenous TGF-β.

[0081] 4.6.3. Example 3: TGFBR2-disrupted TCR-expressing T cells maintain proliferative capacity in the presence of TGF-β This example shows that TGFBR2-disrupted T cells are able to continue to proliferate in the presence of TGF-β.

[0082] 1G4 TCR expressing TGFBR2 disrupted T cells were subjected to repeated restimulation using ImmunoCult (anti-CD3 / CD28 / CD2) Stem Cell Technologies, #10990 in the presence or absence of TGF-β (20ng / mL) R&D systems, #240-B-010 / CF. T cell proliferation was quantified by counting T cells every week (Figure 5). 1G4 TCR only T cells were unable to expand in the presence of TGF-β, whereas TGFBR2 disrupted T cells maintained their ability to expand to the same extent as in the absence of TGF-β. TGFBR2 gRNA4 edited T cells and TGFBR2 gRNA-7 edited T cells (Figure 2), which still retained some functional TGF-β signaling, expanded more slowly in the presence of TGF-β compared to the other TGFBR2 disrupted T cells.

[0083] This data indicates that TGFBR2 KO T cells are resistant to TGF-β-mediated inhibition of proliferation and can maintain their proliferative potential in the presence of TGF-β.

[0084] 4.6.4. Example 4: TGFBR2-disrupted TCR-expressing T cells have similar levels of TCR expression. This example shows that TGFBR2-disrupted T cells express similar levels of exogenous TCR as non-disrupted cells.

[0085] TCR knock-in TGFBR2-disrupted T cells were engineered by simultaneously electroporating TGFBR2, TRAC and TRBC targeting Cas9-gRNA ribonucleoprotein complexes (RNPs) and homology-directed repair DNA templates encoding a mutated DHFR gene that is resistant to methotrexate and an exogenous TCR containing a mur6 epitope in the Cβ domain (described in U.S. Patent Application No. 17 / 557,514, which is incorporated herein in its entirety).

[0086] Cells were grown for 7 days after electroporation and then selected using methotrexate according to the method described in US Patent Publication No. 2022 / 0041999 (incorporated herein by reference in its entirety). Expression of endogenous TCR was determined by staining with an antibody (antibody clone IP26) that recognizes the human TCRαβ complex. Expression of exogenous TCR was detected with an antibody (H57) that recognizes the mur6 epitope.

[0087] Seven days after electroporation, T cells expressed the exogenous TCR at comparable levels in all conditions tested (no TGFBR2 disruption, TGFBR2 disruption with three different targeting sequences, and AAVS1 control KO), both before selection 7 days after electroporation and after selection 14 days after electroporation (Figure 5).

[0088] This data indicates that TGFBR2 KO T cells were not impaired in their ability to express an exogenous TCR.

[0089] 5. Equivalents and Incorporation by Reference While the present invention has been particularly shown and described with reference to preferred and various alternative embodiments, it will be understood by those skilled in the art that various changes in form and detail can be made therein without departing from the spirit and scope of the invention.

[0090] All references, issued patents, and patent applications cited within the body of this specification are hereby incorporated by reference in their entirety for all purposes.

Claims

1. 1. A T cell comprising an engineered genomic modification of a TGFBR2 gene, wherein the engineered genomic modification results in a level of surface-expressed TGFBR2, or a detectable portion thereof, that is about 20% to about 60% of the level of surface-expressed TGFBR2 on a corresponding control cell.

2. The T cell of claim 1 , which is a CD8+ αβ T cell, a CD4+ αβ T cell, or a γδ T cell.

3. The T cell of claim 1 or 2, which is a human T cell.

4. The T cell of any one of claims 1 to 3, wherein the surface expressed TGFBR2 or detectable portion thereof is capable of binding to TGF-β but is incapable of phosphorylating TGFBR1.

5. The T cell of any one of claims 1 to 4, which is unable to effectively signal through Smad2 / 3 in response to contact of said T cell with physiologically relevant levels of TGF-β.

6. 6. The T cell of any one of claims 1 to 5, wherein the engineered genomic modifications comprise one or more of: (i) insertions and / or deletions in the TGFBR2 gene promoter; (ii) frameshift insertions and / or deletions in exons of the TGFBR2 gene; (iii) a deletion of part, but not all, of the coding region of the TGFBR2 gene; (iv) substitutions, insertions and / or deletions that create a stop codon in an exon upstream of a naturally occurring stop codon; and (v) substitutions, insertions and / or deletions that modify one or more donor and / or acceptor site RNA splice sites within the TGFBR2 gene.

7. The T cell of any one of claims 1 to 6, wherein the genomic modification is in exon 4 of the TGFBR2 gene.

8. 8. The T cell of claim 7, wherein the genomic modification is a frameshift caused by cleavage by an RNA-guided nuclease between bases 294 and 295, 389 and 390, 543 and 544, 547 and 548, or 674 and 675 of exon 4 (SEQ ID NO:2) of the TGFBR2 gene.

9. The T cell of any one of claims 1 to 8, expressing an exogenous TCR or CAR, preferably an exogenous TCR.

10. The T cell of claim 9 , which expresses an exogenous TCR.

11. The T cell of claim 10, wherein the foreign TCR recognizes a tumor antigen, preferably a tumor neo-antigen.

12. The T cell of claim 11 , wherein the tumor antigen is a neoantigen.

13. The T cell of claim 12 , wherein the tumor antigen is a common tumor neo-antigen.

14. The T cell of claim 12, wherein the tumor antigen is a non-common tumor neo-antigen.

15. 15. The T cell of any one of claims 9 to 14, which maintains the ability to kill in vitro a population of target cells expressing the antigen recognized by the exogenous TCR or CAR in the presence of physiologically relevant levels of TGF-β after at least two exposure events to target cells.

16. 16. The T cell of any one of claims 9 to 15, which maintains the ability to kill a population of target cells expressing the antigen recognized by the exogenous TCR or CAR in vitro for at least about 72, 80, 90, 100, 110, 120, 130, 140, 144, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280 or 288 hours in the presence of physiologically relevant levels of TGF-β.

17. A T cell comprising an engineered genomic modification of the TGFBR2 gene, said modification resulting in a surface-expressed TGFBR2 that is a truncated form.

18. 18. The T cell of claim 17, which is a CD8+ αβ T cell, a CD4+ αβ T cell or a γδ T cell.

19. 19. The T cell of claim 17 or 18, which is a human T cell.

20. The T cell of any one of claims 17 to 19, wherein the truncated, surface-exposed TGFBR2 is capable of binding to TGF-β but is incapable of phosphorylating TGFBR1.

21. 21. The T cell of any one of claims 17 to 20, which is unable to signal effectively through Smad2 / 3 in response to contact of said T cell with physiologically relevant levels of TGF-β.

22. 22. The T cell of any one of claims 17-21, wherein the engineered genomic modification comprises one or more of: (i) a frameshift insertion and / or deletion in exon 4 of the TGFBR2 gene; (ii) a deletion of exons 5-7 of the TGFBR2 gene, optionally combined with a total or partial deletion of exon 4; and (iii) a substitution, insertion and / or deletion in exon 4 creating a premature stop codon.

23. 23. The T cell of claim 22, wherein the genomic modification is a frameshift caused by cleavage by an RNA-guided nuclease between bases 294 and 295, 389 and 390, 543 and 544, 547 and 548, or 674 and 675 of exon 4 (SEQ ID NO:2) of the TGFBR2 gene.

24. The T cell according to any one of claims 17 to 23, expressing an exogenous TCR or CAR, preferably an exogenous TCR.

25. The T cell of claim 24, which expresses an exogenous TCR.

26. The T cell of claim 25, wherein the foreign TCR recognizes a tumor antigen, preferably a tumor neo-antigen.

27. 27. The T cell of claim 26, wherein the tumor antigen is a neoantigen.

28. 28. The T cell of claim 27, wherein the tumor antigen is a common tumor neo-antigen.

29. 28. The T cell of claim 27, wherein the tumor antigen is a non-common tumor neo-antigen.

30. 30. The T cell of any one of claims 24 to 29, which maintains the ability to kill in vitro a population of target cells expressing the antigen recognized by the exogenous TCR or CAR in the presence of physiologically relevant levels of TGF-β after at least two exposure events to target cells.

31. 31. The T cell of any one of claims 24-30, which maintains the ability to kill a population of target cells expressing the antigen recognized by the exogenous TCR or CAR in vitro for at least about 72, 80, 90, 100, 110, 120, 130, 140, 144, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280 or 288 hours in the presence of physiologically relevant levels of TGF-β.

32. A pharmaceutical composition comprising the T cells of any one of claims 1 to 31 and a pharma- ceutically acceptable carrier.

33. 33. The pharmaceutical composition of claim 32, adapted for administration by intravenous infusion.

34. 33. The pharmaceutical composition of claim 32, adapted for intratumoral administration.

35. 1. A method of genetically engineering a T cell, comprising modifying a TGFBR2 gene in the genome of the T cell, wherein after genetic modification, the level of surface-expressed TGFBR2, or a detectable portion thereof, is from about 20% to about 60% of the level of surface-expressed TGFBR2 on a corresponding control cell.

36. 36. The method of claim 35, wherein the T cells are CD8+ αβ T cells, CD4+ αβ T cells, or γδ T cells.

37. 37. The method of claim 35 or 36, wherein the T cell is a human T cell.

38. The method of any one of claims 35 to 37, wherein the surface expressed TGFBR2 or detectable portion thereof is capable of binding to TGF-β but is incapable of phosphorylating TGFBR1.

39. 39. The method of any one of claims 35-38, wherein the modification prevents the T cell from effectively signaling through Smad2 / 3 in response to contact of the T cell with physiologically relevant levels of TGF-β.

40. 40. The method of any one of claims 35 to 39, wherein the modification is one or more of: (i) insertions and / or deletions in the TGFBR2 gene promoter; (ii) frameshift insertions and / or deletions in exons of the TGFBR2 gene; (iii) deletions of part, but not all, of the coding region of the TGFBR2 gene; (iv) substitutions, insertions and / or deletions that create a stop codon in an exon upstream of a naturally occurring stop codon; and (v) substitutions, insertions and / or deletions that modify one or more donor and / or acceptor RNA splice sites within the TGFBR2 gene.

41. 41. The method of claim 40, wherein the modification is in exon 4 of the TGFBR2 gene.

42. 42. The method of any one of claims 35 to 41, wherein modifying comprises introducing an RNA-guided nuclease and at least one RNA guide into said T cell.

43. 43. The method of claim 42, wherein the RNA-guided nuclease cleaves between bases 294 and 295, 389 and 390, 543 and 544, 547 and 548, or 674 and 675 of exon 4 (SEQ ID NO:2) of the TGFBR2 gene.

44. 44. The method of claim 43, wherein at least one of the at least one guide RNAs has a sequence of SEQ ID NO: 8-12.

45. 45. The method of any one of claims 35 to 44, further comprising a subsequent step of selecting T cells carrying the desired genomic modification.

46. 46. ​​The method of any one of claims 35 to 45, further comprising the step of genetically engineering said T cells to express an exogenous TCR or CAR, preferably an exogenous TCR, before or after modifying the TGFBR2 gene.

47. 47. The method of claim 46, wherein the T cells are genetically engineered to express an exogenous TCR.

48. 48. The method of claim 47, wherein the foreign TCR recognizes a tumor antigen, preferably a tumor neo-antigen.

49. 49. The method of claim 48, wherein the tumor antigen is a neoantigen.

50. 50. The method of claim 49, wherein the tumor antigen is a common tumor neo-antigen.

51. 50. The method of claim 49, wherein the tumor antigen is a non-common tumor neo-antigen.

52. 52. The method of any one of claims 35-51, wherein the T cells maintain the ability to kill in vitro a population of target cells expressing the antigen recognized by the exogenous TCR or CAR in the presence of physiologically relevant levels of TGF-β after at least two exposure events to target cells.

53. 53. The T cell of any one of claims 35-52, which maintains the ability to kill a population of target cells expressing the antigen recognized by the exogenous TCR or CAR in vitro for at least about 72, 80, 90, 100, 110, 120, 130, 140, 144, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280 or 288 hours in the presence of physiologically relevant levels of TGF-β.

54. 1. A method of genetically engineering a T cell, comprising modifying a TGFBR2 gene in the T cell genome, said modification being within exon 4 and resulting in a surface expressed TGFBR2 that is truncated.

55. 55. The method of claim 54, wherein the T cells are CD8+ αβ T cells, CD4+ αβ T cells, or γδ T cells.

56. 56. The method of claim 54 or 55, wherein the T cell is a human T cell.

57. 57. The method of any one of claims 54 to 56, wherein the surface expressed TGFBR2 or detectable portion thereof is capable of binding to TGF-β but is incapable of phosphorylating TGFBR1.

58. 58. The method of any one of claims 54-57, wherein the modification prevents the T cell from effectively signaling through Smad2 / 3 in response to contact of the T cell with physiologically relevant levels of TGF-β.

59. 59. The method of any one of claims 54 to 58, wherein the truncated surface expressed TGFBR2 is present at a level equal to or greater than the amount of TGFBR2 present in unmodified T cells.

60. 59. The method of any one of claims 54-58, wherein the truncated surface expressed TGFBR2 is present at a level that is about 20% to 60% of the level of TGFBR2 present in unmodified T cells.

61. 61. The method of any one of claims 54 to 60, wherein the engineered genomic modification comprises one or more of: (i) a frameshift insertion and / or deletion in exon 4 of the TGFBR2 gene; (ii) a deletion of exons 5-7 of the TGFBR2 gene, optionally combined with a total or partial deletion of exon 4; and (iii) a substitution, insertion and / or deletion in exon 4 creating a premature stop codon.

62. 62. The method of any one of claims 54 to 61, wherein modifying comprises introducing an RNA-guided nuclease and at least one guide RNA into said T cell.

63. 63. The method of claim 62, wherein the RNA-guided nuclease cleaves between bases 294 and 295, 389 and 390, 543 and 544, 547 and 548, or 674 and 675 of exon 4 (SEQ ID NO:2) of the TGFBR2 gene.

64. 64. The method of claim 63, wherein at least one of said at least one guide RNA has a sequence of SEQ ID NO: 8-12.

65. 65. The method of any one of claims 54 to 64, further comprising a subsequent step of selecting T cells carrying the desired genomic modification.

66. 66. The method of any one of claims 54 to 65, further comprising the step of genetically engineering said T cells to express an exogenous TCR or CAR, preferably an exogenous TCR, before or after modifying the TGFBR2 gene.

67. 67. The method of claim 66, wherein the T cells are genetically engineered to express an exogenous TCR.

68. 68. The method of claim 67, wherein the foreign TCR recognizes a tumor antigen, preferably a tumor neo-antigen.

69. 69. The method of claim 68, wherein the tumor antigen is a neoantigen.

70. 70. The method of claim 69, wherein the tumor antigen is a common tumor neo-antigen.

71. 70. The method of claim 69, wherein the tumor antigen is a non-common tumor neo-antigen.

72. 72. The method of any one of claims 54-71, wherein the T cells maintain the ability to kill in vitro a population of target cells expressing the antigen recognized by the exogenous TCR or CAR in the presence of physiologically relevant levels of TGF-β after at least two exposure events to target cells.

73. 53. The method of any one of claims 35-52, wherein the T cells maintain the ability to kill a population of target cells expressing the antigen recognized by the exogenous TCR or CAR in vitro for at least about 72, 80, 90, 100, 110, 120, 130, 140, 144, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 288 hours in the presence of physiologically relevant levels of TGF-β.

74. A genetically engineered T cell produced by the method of any one of claims 35 to 73.

75. 75. A pharmaceutical composition comprising the genetically engineered T cell of claim 74 and a pharma- ceutically acceptable carrier.

76. 13. A method of treating a patient, comprising administering to the patient a therapeutically effective amount of the engineered T cell of any one of claims 1 to 31 or the pharmaceutical composition of claim 32 or 75.

77. 75. The T cell of any one of claims 9-16 or 24-31 or the engineered T cell of claim 74, wherein the exogenous TCR or CAR has been engineered into the T cell using site-specific integration.

78. 78. The T cell or genetically engineered T cell of claim 77, wherein site-specific integration is achieved by CRISPR, optionally CRISPR-Cas9.

79. 75. The T cell of any one of claims 9 to 16 or 24 to 31 or the engineered T cell of claim 74, wherein the exogenous TCR or CAR is integrated at a defined location in the genome of the T cell or engineered T cell.

80. 80. A pharmaceutical composition comprising a T cell or a genetically engineered T cell according to any one of claims 77 to 79 and a pharma- ceutically acceptable carrier.

81. 81. The pharmaceutical composition of claim 80, adapted for administration by intravenous infusion.

82. 81. The pharmaceutical composition of claim 80, adapted for intratumoral administration.

83. 73. The method of any one of claims 46-53 or 66-72, wherein the exogenous TCR or CAR is integrated at a defined location in the genome of the T cell.

84. 84. The method of claim 83, wherein said integration is performed using CRISPR, optionally CRISPR-Cas9.